Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) metastatic to the brain
ÌÇÐÄ´«Ã½
Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) metastatic to the brain Chow, L. Q., Barlesi, F., Bertino, E. M., van den Bent, M. J., Wakelee, H., Wen, P. Y., Chiu, C., Orlov, S., Majem, M., Chiari, R., McKeage, M., Yu, C., Hurtado, F. K., Arratia, P., Song, Y., Branle, F., Shi, M., Kim, D. OXFORD UNIV PRESS. 2019: 602–3View details for